Cargando…
COVID-19: Wait for a novel drug or act with the age old drug – Do we have a choice?
Autores principales: | Thangaraju, Pugazhenthan, gurunthalingam, Meenalotchini Prakash, venkatesan, Sajitha, Thangaraju, Eswaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211657/ https://www.ncbi.nlm.nih.gov/pubmed/32451256 http://dx.doi.org/10.1016/j.jiph.2020.05.006 |
Ejemplares similares
-
COVID-19: Older drugs for a novel disease—Chloroquine, hydroxychloroquine, and possible Pentoxifylline—set to start the second innings?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Can HCQ Be Considered a “Safe Weapon” for COVID-19 in the Indian Population?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Chloroquine induced utricaria—A detailed history helps
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019) -
Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020)